Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ICoN-1: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Clofazimine Inhalation Suspension When Added to Guideline-Based Therapy in Participants With Nontuberculous Mycobacterial Infection

NCT06418711 is registered in ClinicalTrials.gov with Mannkind Corporation as lead sponsor.

NCT NCT06418711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06418711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ICoN-1: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Clofazimine Inhalation Suspension When Added to Guideline-Based Therapy in Participants With Nontuberculous Mycobacterial Infection
Lead sponsor
Mannkind Corporation
Phase
Phase 3
Overall status
Terminated
Start date
September 11, 2024
Completion date
November 10, 2025
Enrollment
132 (actual)
Sites
99

Conditions

As the registry lists them; a condition with its own page is linked.

mac lung disease, mycobacterium infections, nontuberculous, treatment refractory mac lung disease